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INTRODUCTION
Ovarian cancer is the leading cause of mortality
from the gynecologic malignancies (Jermal et al,
2004). Every year, 2,000 ovarian cancer cases are
being newly diagnosed and approximately 1,000
deaths, secondary to the malignancy, occur
annually in Korea (Ministry health and welfare,
2001). Epithelial ovarian cancer (EOC), the most
common form of human ovarian cancer, is usually
diagnosed at stage III or IV, a stage at which the
5-year survival rate is below 30% compared with a
95% survival rate for stage I (Jermal et al, 2004).
To improve patient survival, the identification and
characterization of the key bio-markers that
participate in ovarian carcinogenesis would be the
essential steps.
Presently, lots of molecular knowledge has been
piling up in the oncologic field. Based on the
knowledge of differentially expressed genes in
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To identify new bio-markers as well as potential targets for new drugs for epithelial ovarian cancer (EOC), we compared the gene expression
profiles of cancer tissues from 25 EOCs with human ovarian surface epithelium (HOSE) using in-house cDNA microarray specified to
EOC. Based on a comprehensive method and information from the National Cancer Institute (NCI) Cancer Genome Anatomy Project
(CGAP), the cDNA library was constructed. After excluding the overlapping clones, 768 spots were included in the array. We identified
the genes and expressed sequence tags (ESTs) (30 up-regulated and 34 down-regulated) that are differentially expressed in EOC tissues.
To confirm the expression data, we performed real time RT-PCR experiments. Using microdissected EOC tissues and cell lines, we
investigated the expression status of the NET-1 gene, clusterin gene, and actin-binding LIM protein 1. The information provided here will
be useful for identifying genes whose products might serve as molecular signatures for the biomakers of EOCs.
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ovarian cancers, we are beginning to understand
the biological behavior of the ovarian cancer cells.
Several genes have been considered as candidates
for the bio-markers of EOC, such as p53 (Aunoble
et al, 2000), K-ras (Alvarez et al, 2001), ErbB2
(Leng et al, 1997), and Myc (Itkes et al, 1990).
Moreover, many genes have recently been included
as a candidate gene, such as DOC-2 (Mok et al,
1998), and kallikrein 4,5,8,9 (Kim et al, 2001;
Yousef et al, 2001; Kishi et al, 2003; Yousef et
al, 2003). However, the inconsistency for
expression of the genes shows poor or incomplete
understanding about EOC tumorigenesis.
Moreover, researchers haven‘t found good
parameters for distinguishing the subtypes of EOC
and their biological behaviors.
To arrive a better understanding of efficiently
the genetic events that contribute to EOC, it has
been suggested to identify those genes that are
differentially expressed, and that may be directly
related to tumorigenesis. cDNA microarray is
known to be a powerful tool to identify numerous
differentially expressed genes during the
neoplastic progression of EOC (Ono et al, 2000;
Wong et al, 2001; Jazaeri et al, 2003; Yang et al,
2003). It allows a number of potential candidate
genes to be selected for subsequent analysis and
applications, such as prostasin (Mok et al, 2001),
EP-CAM (Kim et al, 2003), and osteopontin
(Kim et al, 2002). However, because this gene
expression analysis have been performed on arrays
containing a limited set of genes, more studies are
needed to characterize EOC.
Recently, by using a small and specialized chip
that includes only the genes relevant to the
biological process of interest, we can get the
advantage of statistical power and eliminating
noise (Sawiris et al, 2002).
In this study, we report on how we employed a
home-made cDNA microarray specified to EOC to
investigate genes differentially expressed in EOC.
MATEARIAL AND METHODS
1. Preparation of the ovarian Tumor-specific
cDNA microarray (OVCA Chip V1.0)
To make the ovarian tissue-specific cDNA array,
we used a comprehensive human ovarian tumor
cDNA library and clones sequenced by the National
Cancer Institute (NCI)s Cancer Genome Anatomy
Project (CGAP). A comprehensive human ovarian
tumor cDNA library in the Lambda ZAP-CMV
vector was custom-made using the mRNA samples
obtained from 64 ovarian tumor tissues of
different histological subtypes, grades, and stages
(Stratagene, La Jolla, CA). To prepare the DNA of
the lambda cDNA clones, the library was plated
onto agar plates consisting of 0.7% top agarose.
Agar plugs containing well-isolated single
bacteriophage plaques were picked and placed into
1 mL suspension medium (0.1 M NaCl, 8 mM
MgSO4, 50 mM Tris.Cl, pH 7.5, 0.1% gelatin) with
one drop of chloroform. More than 500 single
plaques were harvested. After an overnight elution
at 4 , the phages from each single plague were℃
incubated with E. coli XL1-Blue MRF cells and
plated again. Plate lysates of the individual cDNA
clones were harvested and the lambda DNA
samples were extracted from these clones using
the Qiagen Lambda System and the cDNA inserts
were PCR-amplified with T7 and T3 primers. After
checking their sizes and integrity on 1% agarose
gels, the cDNA clones were sequenced by using ABI
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PRISM BigDye Termination Cycle Sequencing on an
ABI PRISM 310 Genetic Analyzer. Three hundred
and fifty unique sequences were so obtained.
The National Cancer Institute (NCI) Cancer
Genome Anatomy Project (CGAP) has determined
the gene expression profiles of normal, pre-
cancerous, and cancer cells by generating more
than 400 CGAP libraries and sequencing thousands
of clones from each library. The CGAP web site
allows researchers to search and analyze all CGAP
libraries and other cDNA libraries. Using the cDNA
xProfiler software at the CGAP website, we were
able to identify 9 ovarian tumor libraries that were
derived from microdissected ovarian tumor cells.
A total of 7,706 sequenced clones from these 9
different CGAP microdissected ovarian tumor
libraries were purchased from Incyte Genomics,
Inc (Palo Alto, California) (Table 1).
By comparing the gene expression between these
pools of ovarian tumor cDNA libraries with the
rest of the cDNA libraries (~6000), a list of 294
genes that are unique to these 9 ovarian tumor
libraries was identified. From the sequencing
analysis, 12 of these clones have similarity to the
Alu repeat and 8 of these clones are no longer in
Table 1. CGAP microdissected ovarian tumor libraries
Library name No.of unique genesa Characteristics (microdissected tumors)
NCI_CGAP_Ov26 98 ovary papillary serous carcinoma
NCI_CGAP_Ov31 39 ovary invasive tumor
NCI_CGAP_Ov32 118 ovary invasive tumor
NCI_CGAP_Ov33 17 ovary borderline (LMP)
NCI_CGAP_Ov34 24 ovary borderline (LMP)
NCI_CGAP_Ov36 19 ovary borderline (LMP)
NCI_CGAP_Ov37 1 ovary early stage papillary serous carcinoma
NCI_CGAP_Ov39 31 ovary papillary serous ovarian metastasis to the omentum
NCI_CGAP_Ov40 74 ovary endometrioid ovarian metastasis to the omentum
a Some of the unique genes are present in more than one of these libraries.
the unigene database.
Using these 294 ovarian unique expressed
sequence tags (ESTs) from the CGAP, 452 known
genes and ESTs from our own ovarian tumor
library and the normal HOSE cDNA library
generated from microdissected normal HOSE cells,
19 house keeping genes, and 3 arabidopsis spike
control, we have constructed an ovarian specific
cDNA microarray composed of total of 768 spots.
The clones were rearrayed into two 384 well
plates, PCR amplified and purified. The PCR
products were re-sequenced and printed onto
GAPS slides (Corning Inc., Fountain valley, CA)
in duplicate using a PixSys 5,500XL arrayer
(Cartesian Technologies, Irvine, CA). A typical
result is shown in Fig. 1.
2. Gene expression analysis of 25 ovarian tumors
We used this ovarian specific microarray to
analyze the expression profiles of 25 ovarian
tumors that included 9 serous grade III, 4 serous
grade I, 4 mucinous, 4 clear cell and 4
endometrioid histological subtypes. The relevant
clinical features of these patients are summarized
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Fig. 1. Quantitation of differential hybridization signals between
normal ovarian surface epithelial cells (green) and ovarian
cancer cells (red) from a home-made ovarian specific cDNA
microarray with 768 genes printed in duplicate. Analysis was
done with software Imagene 4.2. Yellow means almost equal
signals from both samples. One microgram of total RNA from
tumor or HOSE cells was labeled with the MICROMAX TSA
system.
in Table II. A pool of 6 independent human ovarian
surface epithelial primary cell cultures was used
as the reference RNA. The TSA indirect labeling
method was adopted in this study because of the
limited amount of total RNA from the samples.
Briefly, 1 µg of total RNA from tumor sample was
labeled with biotin-dUTP during cDNA synthesis,
while the reference RNA was labeled with
fluorescein-dUTP. After hybridization, the signals
from the tumor and reference sample were
amplified with tyramide-Cy3 and tyramide-Cy5
respectively in the presence of horseradish
peroxidase. After hybridization, the slides were
scanned with a dual laser scanner, ScanArray
3,000 (General Scanning, now part of Perkin
Elmer Life Sciences, Boston, MA). The
hybridization signals were analyzed with software
Imagene 4.2 (Biodiscovery Inc., Marina Del Rey,
CA) and the hybridization signals were normalized
to the median signal of 19 house-keeping genes.
In addition, another method of data analysis
developed by Tseng et al (2001) was also used. In
briefly, for comparing two different conditions
using cDNA microaray data, a quality index and
calibration experiments for normalization were
used. A rank invariant method was suggested to
select non-differentially expressed genes and to
construct normalization curves in comparative
experiments. After normalization, the residuals
from the calibration data are used to provide prior
information on variance components in the
analysis of comparative experiments.
Hierarchical clustering was performed using
J-Express (Version 2.1).
3. Cell lines and culture conditions
All cell lines and cultures were maintained at
37 in a humidified 5% CO℃ 2 ambient air
atmosphere. They were grown in Medium 199
and MCDB 105 (1:1) (Sigma, St Louis, MO)
supplemented with 10% fetal bovine serum (Gemini
Bio-Products, Calabasas, CA). Normal human
ovarian surface epithelial cells (HOSE) cultures
were established by scraping the surface of the
ovary, as described previously (Tsao et al, 1995).
In brief, the scraped cells were spun down,
resuspended and cultured in 2.5 mL of growth
medium. Cells at 75% confluenc were then
harvested by trypsinization and used for the total
RNA isolation. For real time PCR, we prepared 9
HOSE cells and 21 ovarian cancer cell lines.
Normal HOSE cells used in this experiment were
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HOSE601, HOSE667, HOSE696, HOSE 713,
HOSE718, HOSE 726, HOSE730, HOSE806, and
HOSE831. Ovarian cancer cell lines were used
ALST, CAOV3, DOV13, OVCA3, SKOV3, OVCA429,
OVCA432, OVCA433, OVCA633, OVCA680,
OVCA702, OVCA5071, PEO4, TOV112, TOV21,
2008PO4, MCAS, RMUG-L, RMUG-S, RMG-1 as
well as ES-2. MCAS, RMUG-L and RMUG-S were
originated from ovarian mucinous cystadenocar-
cinoma. TOV112 was originated from ovarian
endometrioid adenocarcinoma. TOV21, RMG-1 and
ES-2 were originated from clear cell carcinoma.
The others were from serous cystadenocarcinoma.
OVCAR-3, SKOV-3, and ES-2, MCAS, RMUG-L,
RMUG-R and RMG-1, PEO4, and 2008PO4 were
purchased from American Type Culture Collection
(Rockville, MD), the Japanese Collection of
Research Bioresources (Tokyo, Japan), Imperial
Cancer Research Fund, and the University of
Texas Southwestern Medical Center, respectively.
The other cell lines were kindly supplied from the
Laboratory of Gynecologic Oncology, Brigham and
Women's Hospital.
4. Tissue samples
All the patients were treated at Saint Vincent‘s
Hospital between 1995 and 2000. We randomly
retrieved the patients’ tissue specimens having
ovarian tumor with different histologic types and
grades based on the WHO and the International
Federation of Gynecology and Obstetrics criteria.
All tumor tissues were collected from the primary
sites of ovarian cancer. They contained less than
20% normal tissue.
For frozen sections, fresh specimens collected at
the operating room were placed in tissue culture
medium, Medium 199 and MCDB 105 (1:1) with
10% FBS, and then quickly transported to the
laboratory. After removing the nontumorous
tissues, the specimens were immediately embedded
in Tissue Tek OCT medium (Miles, Elkhart, IN),
snap-frozen in liquid nitrogen, and stored at
-80 until use for laser capture microdissection.℃
5. Laser capture microdissection (LCM)
For real time PCR, microdissected tissues were
used. Tissues stored in Tissue Tek OCT medium at
-80 were sectioned at 7 mm in a cryostat (Leica,℃
Allendate, NJ). The sections were mounted onto
uncoated glass slides and immediately fixed in 70%
and 50% ethanol for 30 seconds in each
concentration, then stained with Hematoxylin and
Eosin, and next dehydrated in an increasing series
of alcohol and clear xylene for 5 minutes in each
concentration. The slides were air-dried once for
3 minutes, and next the sections were laser
microdissected with the PixCell II (Arctarus, CA).
Morphologically malignant epithelial ovarian
cancer cells were so procured.
6. Real-time quantitative RT-PCR
RNA was extracted from the cell lines and
tissues using a micro RNA extraction kit as
described by the manufacturer (Stratagene,
Valenica, CA), and quantified by fluorometry
(Gemini Bio-Products). Real-time PCR was
performed in duplicate using primer sets specific
for NET-1 (forward primer: 5‘-CCAGAATGGA
CCTGCCCTTT-3’; reverse primer: 5’-TGGTCCCTA
TCTAGCCCCAA-3’), ABLIM (forward primer:
AACCATAATGCAGAGTGGGCC-3‘; reverse primer:
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CACAACCCATCCCTCCAGC-3’), clusterin (forward
primer: 5‘-TTCCCACACTTCTGACTCGGAC-3’;
reverse primer: 5‘-AACATCCACATCTCACTCC
TCC-3‘) and a house keeping gene, GAPDH
(forward primer: 5’-CATCTCTGCCCCCTCTGCTGA-
3‘; reverse primer 5’-GGATGACCTTGCCCACA
GCCT-3’), in an ABI PRISM 5,700 Sequence
Detector. mRNA was extracted from normal HOSE
cell cultures, ovarian carcinoma cell lines and
normal ovarian tissues, respectively.
cDNA was generated from 1 g total RNA using
the TaqMan reverse transcription reagents
containing 1X TaqMan RT buffer, 5.5 mM MgCl2,
Table 2. Clinical characteristics of 25 cases of epithelial ovarian cancers used in the microarray study
Sample No. Pathologic Subtype Grade Stage Survival*
309 Endometrioid 3 Ⅲ D
316 Endometrioid 3 Ⅲ D
321 Serous 3 Ⅲ D
324 Serous 3 Ⅲ D
329 Endometrioid 1 Ⅲ D
332 Serous 3 Ⅲ D
333 Serous 1 Ⅰ L
334 Serous 3 Ⅲ D
341 Clear 3 Ⅲ D
343 Mucinous 3 Ⅲ D
349 Serous 3 Ⅲ L
351 Serous 3 Ⅲ L
354 Serous 1 Ⅲ L
373 Serous 1 Ⅰ L
375 Serous 3 Ⅲ L
380 Serous 3 Ⅲ D
382 Endometrioid 2 Ⅱ L
386 Serous 3 Ⅲ L
432 Clear 3 Ⅲ D
436 Mucinous 1 Ⅰ D
440 Mucinous 2 Ⅰ L
489 Serous 1 Ⅲ D
622 Clear 3 Ⅲ D
700 Mucinous 2 Ⅰ L
857 Clear 2 Ⅱ D
* D: death, L: live
500 mM dNTP, 2.5 mM random hexamer, 0.4 U/mL
Rnase inhibitor, and 1.25 U/mL MultiScribe
reverse transcriptase (PE Applied Biosystems,
Foster City CA) in a 100 mL. The reaction was
incubated at 25 for 10 minutes, 48 for 30℃ ℃
minutes and finally at 95 for 5 minutes. A total℃
of 0.5 mL of cDNA was used in a 20 mL PCR mix
containing 1X SYBR PCR buffer, 3 mM MgCl2,
0.8 mM dNTP, and 0.025 U/mL AmpliTaq Gold
(PE Applied Biosystems, Foster City, CA).
Amplification was then performed with
denaturation for 10 minutes at 95 , followed by℃
40 PCR cycles of denaturation at 95 for 15℃
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seconds and annealing/extension at 60 for 1℃
minute. The ABI 5,700 system software monitored
the changes in fluorescence of SYBR Green I dye
in every cycle and the threshold cycle (CT) for
each reaction was calculated.
The relative amount of PCR products generated
from each primer set was determined based on the
threshold cycle (CT) value. GAPDH was used for
the normalization of RNA used. Its CT value was
then subtracted from that of each target gene
to obtain a DCT value. The difference (DDCT)
between the DCT values of the samples for each
gene target and the DCT value of the calibrator
was determined. The relative quantitative value
was expressed as 2-DDCT. To confirm the
specificity of the PCR reaction, PCR products
were electrophoresed on a 1.2% agarose gel.
7. Statistical Analysis
Mann-Whitney U-test was used to test
statistical significance for the real time PCR.
The level of critical significance was assigned at
p<0.05. The data were mainly summarized as
means and standard deviations (SD). All analyses
were performed using SPSS version 9.0 (SPSS Inc.,
Chicago, IL).
RESULTS
1. Identification of genes differentially expressed
between EOC tissues and HOSE cells
The cDNA microarray technique was applied to
analyze the expression patterns of EOC tissues
and HOSE cells. Among the relevant 763 genes and
expressed sequence tags (ESTs) assembled in the
cDNA microarray, 64 were found differentially
expressed with the difference signal intensity ratio
of more than 2.0 by a Mann-Whitney U test.
Genes and ESTS were divided into two groups on
the basis of the difference in signal intensity. Out
of 64 differentially expressed genes or ESTs, 30
were up-regulated (a signal intensity ratio of
more than 2) and 34 down-regulated (signal
intensity ratio of less than 1/2) in EOC tissues
compared with HOSE cells (Table 3, 4). The data
were then visualized using the J-express program,
and this process resulted in a dendrogram of genes
grouped together on the basis of the similarity of
each gene's expression pattern (Fig. 2).
Fig. 2. Hierarchical clustering of microarray data. Twenty five
ovarian tumors, which include 9 serous grade III, 4 serous
grade I, 4 mucinous, 4 clear cell, and 4 endometrioid
histological subtypes were used. A pool of 6 independent
human ovarian surface epithelial primary cell cultures was used
as reference RNA. Red indicated genes that were cy-regulated
in tumors compared to normal, and green also indicated genes
that were down regulated in tumor compared to normal. Data
were analyzed using J-Express version 2.1.
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2. Real-time RT-PCR analysis
To further validate the microarry-based
findings, we performed real time RT-PCR
experiments with the NET-1 gene, clusterin gene,
Table 3. Genes and ESTs up-regulated in epithelial ovarian tumor#
Gene name Gene No.* Fold†
NET-1 AF065388 49.8
VK1 S59162 6.2
Ephrin-A1 (EFNA1) M004428 4.8
Ribosomal protein L30 L05095 4.3
FLJ 22875fis AK026528 4.1
Seb4B X75315 3.6
EST Hs.229831 3.0
EST Hs.278748 2.9
HDCMD 47P AF068287 2.8
EST Hs.278749 2.6
EST Hs.278876 2.5
HumFibm for fibrillarin X56597 2.5
EST Hs.278747 2.5
CD 68 M001251 2.5
EST Hs.235247 2.4
EST Hs.278862 2.3
Ribosomal protein S10 (RPS10) M001014 2.3
Actin binding LIM protein1 (ABLIM) M006720 2.3
Clusterin (SP-40) M001831 2.3
EST Hs.235457 2.2
EST Hs.254398 2.2
EST Hs.276352 2.1
Aldehyde reductase (AKR1A1) F112482 2.1
EST Hs.176874 2.1
EST Hs.41132 2.1
EST Hs.177415 2.1
FLJ 20203 M017710 2.1
Zinc finger protein (ZNF9) M003418 2.0
EST Hs.245672 2.0
EST H175651 2.0
# More than two fold, P-values <0.05
* GeneBank accession number
† Median value of expression of tumor compared to HOSE
and actin-binding LIM protein 1. The results
confirmed the pattern of expression identified by
the microarray hybridization and showed higher
expression of the genes in most of the EOC cell
lines and tissues (Fig. 3, 4, 5).
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Table 4. Genes and ESTs down-regulated in epithelial ovarian tumor#
Gene name Gene no.* Fold†
Keratin18 (KRT18) P000215 0.1
LIM protein P006448 0.1
EST P006842 0.2
EST AX013703 0.2
| -galactosidase binding proteinβ P002296 0.2
Integrin,beta1 (ITGB1) M002211 0.2
Iron-responsive regulatory protein M58510 0.2
KIAA0109 D63475.1 0.3
Calumenin (CALU) M001219 0.3
Heatshockprotein70 (Hsp70) U69698 0.3
Transcriptional repressor (GCF2) gi|3421044 0.3
Complement component 3 (C3) gi|4557384 0.3
BAC clone RP11-343B21 AC009230 0.3
Ferritin H chain gi|182504 0.3
EST AX018174 0.4
Clone DT1P1A7 gi|2781403 0.4
Clone 23698 gi|3360400 0.4
Serine/threonine proteinkinase 1 gi|5231142 0.4
Platelet-type phosphofructokinase D25328 0.4
EST Hs.274859 0.4
Scofilin1 (CFL1) gi|5031634 0.4
I factor (IF) NM000204 0.4
EST NP005722 0.4
3BACRP11-297K7 AC009319 0.4
EST AC034207 0.4
Alpha-tubulin isoform1m gi|3420928 0.4
RAB7 M004637 0.5
KIAA 0905 gi|4240298 0.5
EST Hs.278762 0.5
TATA box binding protein (TBP)-associated factor M003187 0.5
Rab11 X56740 0.5
Eukaryotic translation initiation factor 4 gamma 2 M001418 0.5
EST Hs.63472 0.5
Actin, gamma1 (ACTG1) M001614 0.5
# More than two fold, P-values <0.05
* GeneBank accession number
† Median value of expression of cancer to HOSE
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Fig. 3. Relative quantitation of NET-1 mRNA in HOSE cells
and epithelial ovarian cancers. A. Statistically significant
differences were not obtained between normal HOSE cells
(HOSE 601, HOSE 667, HOSE 696, HOSE 697, HOSE 718)
and ovarian cancer cell lines (TOV21, TOV112, SKOV 3,
2008PO4, PEOH, RMUG-L, RMUG-S, RMG-1, ES-2) by the
Mann-Whitney U Test. B. Expression differences were
statistically obtained between 5 HOSE cells and 18 cancer
tissues by the Mann-Whitney U-test (p<0.01). Each value was
expressed as the mean of the duplicates.
DISCUSSIONS
The majority of women with ovarian cancer are
diagnosed when they have distant metastatic
disease. Primary surgical treatment is seldom
curative for late stage disease and adjuvant
treatment with radiation or chemotherapy is
indispensable. At present, an accurate and
reliable, screening method for earley detection has
not yet been developed. An early detection method
that has been suggested is the use of pelvic
ultrasound, but this approach has limitations.
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Fig. 4. Relative quantitation of ABLIM mRNA in HOSE cells
and epithelial ovarian cancers. A. Statistically significant
differences were obtained between normal HOSE cells (HOSE
601, HOSE 667, HOSE 696, HOSE 697, HOSE 718) and
ovarian cancer cell lines (TOV21, TOV112, SKOV 3,
2008PO4, PEOH, RMUG-L, RMUG-S, RMG-1, ES-2) by the
Mann-Whitney U Test (p<0.05). B. Expression differences were
statistically obtained between 5 HOSE cells and 18 cancer
tissues by the Mann-Whitney U-test (p<0.01). Each value was
expressed as the mean of the duplicates.
Pelvic ultrasound is high in cost and it may lead to
unnecessory surgery with its attendant costs and
potential morbidity for many non-cancerous cysts
of the ovary for every case of ovarian cancer
detected (Karlan, 1995). At the same time, there
are case reports of ovarian cancers involving only
the surface of the ovary that were detected at the
time of prophylactic oophorectomy but thtse
lesions had not been seen on the pelvic
ultrasounds done shortly before the operation.
Although ultrasound undoubtedly remains an
important component of the work-up for those
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Fig. 5. Relative quantitation of clusterin mRNA in normal and
malignant epithelial ovarian cancer cell lines and tissues. A.
Statistically significant differences were not obtained between
normal ovarian epithelial cells (HOSE 713, HOSE 726, HOSE
730, HOSE 806, HOSE 831) and ovarian cancer cell lines
(ALST, CAOV3, DOV13, OVCA3, SKOV3, OVCA429, OVCA-
432, OVCA433, OVCA633, OVCA680, OVCA702, OVCA5071,
TOV112, 2008, PEOH, TOV21, MCAS, RMUG-L, RMUG-S:
RMG-1, and ES-2) by the Mann-Whitney U Test. OVCA3,
OVCA432, OVCA633, OVCA5071, 2008PO4, PEOH, RMUG-S,
and ES-2 showed highly expressed clusterin. B. Expression
differences were obtained between 8 HOSE cells and 29 cancer
tissues by the Mann-Whitney U-test (p<0.01). Each value was
expressed as the mean of the duplicates.
women at risk for ovarian cancer, it has not been
proved to be an ideal primary screening method.
The use of biologic markers is an appealing
approach to the early detection because such
markers have the potential to detect early ovarian
cancers not visible on ultrasound. Blood specimens
are easily obtained, acceptable to patients, and
could be made inexpensive to assay. There are
currently a number of serum markers for ovarian
cancer: CA-125, OVX1, M-CSF, LPA, and folate-
binding protein (Bast et al, 1981; Bast et al, 1983,
Xu et al, 1993; Suzuki et al, 1995; Suzuki et al,
1998; Xu et al, 1998). While many of these have
good prognostic value, none have been proven to
be effective in early detection. The best studied of
these is CA-125. However, its use in early
detection is limited to clinical trials due to its
uncertain sensitivity for asymptomatic early stage
disease and a lack of specificity in younger women
where an elevated CA-125 may be associated
with benign conditions including endometriosis,
fibroids, pelvic infection, and even menstruation
(Woolas et al, 1993). The CA-125 test may be more
useful in postmenopausal women. It seems clear
that the ideal serologic test for the early detection
of ovarian cancer has not yet been developed.
Microarray analysis of ovarian cancer has
facilitated the rapid identification of potential
diagnostic and therapeutic targets. However, this
is just the beginning of a long journey to fully
understand the pathogenesis of ovarian cancer.
The cDNA microarray analysis of the 768 ovarian
tumor-specific cDNA clones with 25 ovarian
tumors has demonstrated that tumor-specific
genes certainly do exist as potential targets for
developing effective bio-markers. A problem
with current screening method for early cancer
diagnosis is its lack of adequate sensitivity and
specificity. If we can validate the tissue specificity
of these tumor-specific genes and their roles in
the pathogenetic pathways, then we might be able
to develop a more specific diagnostic tool for a
specific tumor type. Likewise, similar strategies
can be applied to other tumors. It will be exciting
to identify all the tissue-specific and tumor-
specific cDNA clones using the CGAP resources
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(Boon et al, 2002), and to use those identified
clones for a tumor specific microarray. By
coupling with the recent advances in data mining
and visualization tools, we might be able to gain a
better understanding of the pathogenetic pathways
for ovarian cancers. By defining the functional
role of each ovarian tumor specific differentially
expressed gene into the context of the altered
cancer pathways, hopefully, we may one day
conquer the scourge of ovarian cancer.
NET-1 is found to be up-regulated by 49.8 fold
in EOC tissues compared with the normal control.
NET-1 is a new member of the tetraspanin family
of proteins. Immunohistochemic analyses of
normal cervical epithelium and that of metaplasia,
condyloma and CIN of differing severity suggest
that NET-1 expression is associated with
neoplastic cell proliferation. The potential
importance for this gene in cervical carcinogenesis
is underlined by an invariably strong expression
of NET-1 observed in all the undifferentiated
squamous cell cancers examined. (Wollscheid et al,
2002). Our data supports the concept of up-
regulation of NET-1 in EOC.
Clusterin is a glycoprotein and it has also been
termed apolipoprotein J, and SP40. It is composed
of two 35-40 kD subunits (α and β) that are
encoded for by a single gene (Rosenberg and
Silkensen, 1995). Clusterin has been proposed to
have functions in the setting of tumorigenesis
including the regulation of apoptosis (Gleave et al,
2001). However, clusterin has recently been
considered as a kind of survival gene because of
its overexpression in the surviving neighboring
cells compared to dead cells (Sensibar et al, 1995).
Moreover, it was shown that clusterin expression
is up-regulated in response to stress agents
like heat, cytotoxic drugs, UVA exposure, and
oxidative stress (Viard et al, 1999; Dumont et al,
2000). Although the exact role of clusterin is not
known, we can recognize the possibility of it being
biomarker of EOC.
Actin binding LIM protein 1 is known as a key
molecular adaptor with a remarkable potential to
mediate protein-protein interactions. Its other
ability is related to cofactor exchange that
provides a molecular basis for its pleiotropic
functions (Matthews et al, 2003).
Many of the candidate genes as molecular bio-
markers were screened rapidly in this study. Our
in-house cDNA microarray system is an efficient
tool to analyze the expression status of the genes
in an ovary. The large number of differentially
expressed genes identified by this analysis and the
characterization of theses genes will lead us to
develop effective biomarkers as targets for earley
diagnosis and treatment.
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국문초록= =
상피성 난소암의 생화학적 표지물질을 발견하기 위하여 개의 상피성 난소암 조직의 유전자 표현 양상을 종양특이, 25
를 이용하여 비교하였다 와cDNA microarray . Comprehensive method National Cancer Institute (NCI)s Cancer Genome
의유전자정보를이용하여 반복되는 을제외한 개의 으로구성된 를구축하였Anatomy Project (CGAP) , clone 768 spot array
다 상피성난소암조직에서상이하게발현되는 개의유전자또는 를발견하였다 유전자. 64 ESTs (expressed sequence tags) .
발현여부를확실하게알기위하여미세조작된상피성난소암조직과세포주를이용하여 을시행하였Real time RT- PCR
다 유전자의 발현이 상피성 남소암에서 과발현됨을 확인할 수 있었다 본. NET-1, clusterin, actin-binding LIM protein 1 .
연구는상피성난소암의진단에있어서 으로작용될수있는물질을생성하는유전자를밝혀내는데유용molecular target
한 정보를 제공할 수 있을 것이다.
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